神经诊断市场规模、份额和成长分析（按疾病、技术、最终用途和地区划分）－2026-2033年产业预测

预计到 2024 年，神经诊断市场规模将达到 107.9 亿美元，到 2025 年将达到 117.6 亿美元，到 2033 年将达到 234.3 亿美元，在预测期（2026-2033 年）内，复合年增长率为 9%。

神经诊断市场的主要驱动力是神经系统疾病发生率的上升、人口老化以及技术的显着进步。这些创新透过融合蛋白质体学和基因组学的新型诊断技术，提高了神经退化性疾病准确性，从而实现了疾病的早期精准检测。在全球范围内，医院和诊断中心数量的增加，透过提升先进诊断技术的可近性，加速了市场成长。神经诊断中对生物学分析的需求不断增长，也进一步推动了这个趋势。然而，也存在一些潜在挑战，例如一些开发中国家严格的法规环境和对神经诊断服务需求疲软。儘管如此，神经诊断技术在临床研究中的日益广泛应用，正在开闢新的市场机会，尤其是在医疗基础设施不断完善、支出不断增长的新兴经济体，这为充满活力的行业前景奠定了基础。

神经诊断市场驱动因素

神经诊断市场的成长主要受神经系统疾病（包括癫痫、帕金森氏症和阿兹海默症）盛行率上升的驱动。随着这些疾病患者数量的持续增长，医疗机构对先进诊断技术的需求也日益增加。这种需求的激增推动了先进神经诊断工具的应用，以实现疾病的精准识别和后续观察，从而促进了整个市场的发展。此外，改善患者预后和提升诊断能力的努力也进一步推动了神经诊断技术的扩张。

神经诊断市场的限制因素

神经诊断市场面临的一大挑战是严格的监管，这些监管涵盖了神经诊断设备的批准和销售。冗长的流程和复杂的指南可能会扼杀创新，减缓新技术的应用，最终限制市场的成长潜力。在医疗保健监管严格的地区，这种情况尤其突出，合规方面的复杂性可能成为新技术进入市场的障碍。因此，整个神经诊断市场的发展可能会受到阻碍，进而阻碍能够改善患者照护和治疗方案的关键诊断工具的研发。

神经诊断市场趋势

神经诊断市场正日益受到基因组学和个人化医疗进步的影响，这些进步正在改变神经系统疾病的诊断和治疗方法。借助尖端的基因分析技术，医疗机构能够为每位患者提供更有效、更个人化的治疗方案，进而推动精准医疗的转型。这一趋势促使人们采用先进的诊断技术，透过专注于特定的基因谱来改善患者照护，最终获得更好的治疗效果。因此，对创新神经诊断工具和调查方法的需求预计将显着增长，这反映了神经病学领域对个人化医疗解决方案的日益重视。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

全球神经诊断市场规模（按产品和复合年增长率划分）（2026-2033 年）

• 诊断和影像系统
  • 脑电图（EEG）系统
  • 肌电图（EMG）产品
  • 磁振造影（MRI）系统
  • 超音波影像设备
  • 电脑断层扫描（CT）扫描仪
  • 脑磁图（MEG）系统
  • 正子断层扫描（PET）系统
  • 血管造影术系统
  • 其他系统
• 临床检测设备
  • PCR
  • 次世代定序（NGS）
  • 桑格定序
  • 其他临床诊断产品
• 试剂和耗材
  • 培养基和血清
  • 溶剂
  • 酵素、蛋白质和胜肽
  • 探测
  • 缓衝
  • 抗体
  • 其他试剂

全球神经诊断市场规模（按疾病和复合年增长率划分）（2026-2033 年）

• 神经退化性疾病
• 癫痫
• 中风
• 头痛疾病
• 睡眠障碍
• 其他疾病

全球神经诊断市场规模（按最终用途和复合年增长率划分）（2026-2033 年）

• 医院及手术中心
• 神经病学中心
• 门诊治疗中心
• 诊断检查室和影像中心
• 研究机构和学术机构

全球神经诊断市场规模（按地区划分）及复合年增长率（2026-2033 年）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• Siemens Healthineers（Germany）
• Thermo Fisher Scientific（US）
• GE Healthcare（US）
• Koninklijke Philips（Netherlands）
• FUJIFILM（Japan）
• Lifelines Neuro（US）
• Advanced Brain Monitoring（US）
• Nihon Kohden（Japan）
• Hoffmann-La Roche（Switzerland）
• Canon Medical Systems（Japan）
• Danaher（US）
• Abbott Laboratories（US）
• Becton, Dickinson and Company（BD）（US）
• Johnson & Johnson（US）
• Medtronic（Ireland）
• Stryker（US）
• Intuitive Surgical（US）
• Zimmer Biomet（US）
• Smith & Nephew（UK）

结论与建议

Neurodiagnostics Market size was valued at USD 10.79 Billion in 2024 and is poised to grow from USD 11.76 Billion in 2025 to USD 23.43 Billion by 2033, growing at a CAGR of 9% during the forecast period (2026-2033).

The neurodiagnostics market is primarily driven by rising neurological disorder incidence, an aging population, and significant technological advancements. These innovations facilitate early and accurate disease detection, enhancing precision in identifying neurodegenerative conditions through novel diagnostic techniques incorporating proteomics and genomics. Globally, the proliferation of hospitals and diagnostic centers accelerates market growth by improving access to advanced diagnostic technologies. Increasing demand for biological profiling in neurological diagnosis further bolsters this trend. However, potential challenges include stringent regulatory environments and low demand for neurodiagnostic services in some developing countries. Conversely, the expanding application of neurodiagnostics in clinical research opens new market opportunities, particularly in emerging economies where healthcare infrastructure is improving and expenditure is rising, setting the stage for a dynamic industry outlook.

Top-down and bottom-up approaches were used to estimate and validate the size of the Neurodiagnostics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Neurodiagnostics Market Segments Analysis

Global Neurodiagnostics Market is segmented by Product, Condition, End-User and region. Based on Product, the market is segmented into Diagnostic and Imaging Systems, Clinical Testing Instruments and Reagents & Consumables. Based on Condition, the market is segmented into Neuro Degenerative Diseases, Epilepsy, Stroke, Headache Disorders, Sleep Disorders and Other Diseases. Based on End-User, the market is segmented into Hospitals and Surgery Centers, Neurology Centers, Ambulatory Care Centers, Diagnostic Laboratories & Imaging Centers and Research Laboratories & Academic Institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Neurodiagnostics Market

The driving force behind the growth of the neurodiagnostics market is the rising prevalence of neurological disorders including epilepsy, Parkinson's disease, and Alzheimer's disease. As the number of individuals affected by these conditions continues to grow, there is a heightened demand for advanced diagnostic technologies within healthcare settings. This surge in demand is prompting the adoption of sophisticated neurodiagnostic tools aimed at accurately identifying and monitoring these disorders, thereby fostering the overall development of the market. Efforts to enhance patient outcomes and improve diagnostic capabilities further support this upward trend in neurodiagnostic technology utilization.

Restraints in the Neurodiagnostics Market

A significant challenge within the neurodiagnostics market stems from stringent regulations governing the clearance and marketing of neurodiagnostic devices. These lengthy processes and intricate guidelines can hinder innovation and slow the deployment of new technologies, ultimately limiting the market's growth potential. This situation is particularly pronounced in regions with stringent healthcare regulations, where the complexities involved in compliance can act as barriers to entry for new advancements. As a result, the overall progress of the neurodiagnostics market may be adversely affected, impeding the evolution of crucial diagnostic tools that could enhance patient care and treatment options.

Market Trends of the Neurodiagnostics Market

The neurodiagnostics market is increasingly influenced by advancements in genomics and personalized medicine, which are transforming the approach to diagnosing and treating neurological disorders. By leveraging cutting-edge genetic analysis, healthcare providers can offer tailored therapies that are more effective for individual patients, facilitating a shift towards precision medicine. This trend is leading to the adoption of sophisticated diagnostic techniques that enhance patient care by focusing on specific genetic profiles, ultimately improving treatment outcomes. As a result, the demand for innovative neurodiagnostic tools and methodologies is poised for significant growth, reflecting a broader commitment to personalized healthcare solutions in neurology.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Neurodiagnostics Market Size by Product & CAGR (2026-2033)

• Market Overview
• Diagnostic and Imaging Systems
  • Electroencephalogram (EEG) Systems
  • Electromyography (EMG) Products
  • Magnetic Resonance Imaging (MRI) Systems
  • Ultrasound Imaging Systems
  • Computed Tomography (CT) Scanner
  • Magnetoencephalogram (MEG) System
  • Position emission tomography (PET) System
  • Angiography System
  • Other Systems
• Clinical Testing Instruments
  • PCR
  • Next-Generation Sequencing (NGS)
  • Sanger Sequencing
  • Other Clinical Diagnostic Products
• Reagents & Consumables
  • Media and Serum
  • Solvents
  • Enzymes, Protein & Peptides
  • Probes
  • Buffers
  • Antibodies
  • Other Reagents

Global Neurodiagnostics Market Size by Condition & CAGR (2026-2033)

• Market Overview
• Neuro Degenerative Diseases
• Epilepsy
• Stroke
• Headache Disorders
• Sleep Disorders
• Other Diseases

Global Neurodiagnostics Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Hospitals and Surgery Centers
• Neurology Centers
• Ambulatory Care Centers
• Diagnostic Laboratories & Imaging Centers
• Research Laboratories & Academic Institutes

Global Neurodiagnostics Market Size & CAGR (2026-2033)

• North America (Product, Condition, End-User)
  • US
  • Canada
• Europe (Product, Condition, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Condition, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Condition, End-User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Condition, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Siemens Healthineers (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GE Healthcare (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Koninklijke Philips (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• FUJIFILM (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lifelines Neuro (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Advanced Brain Monitoring (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nihon Kohden (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hoffmann-La Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Canon Medical Systems (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (BD) (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Stryker (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intuitive Surgical (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zimmer Biomet (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Smith & Nephew (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations